Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-02-23
    E.g., 2018-02-23

Archive Search

Pages

254563 items
7:26 AM, Feb 23, 2018  |  BC Week In Review | Financial News  |  Proposed Offerings

Taiwan Liposome planning NASDAQ listing

Drug delivery company Taiwan Liposome Co. Ltd. (TPEx:4152) proposed to raise up to $50 million on Feb. 17 through the sale of ADSs in a NASDAQ listing underwritten by Cantor Fitzgerald, CLSA, H.C. Wainwright, Janney...
7:25 AM, Feb 23, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

Amicus raises $300M in bumped-up follow-on

Amicus Therapeutics Inc. (NASDAQ:FOLD) raised $300 million on Feb. 15 through the sale of 19.4 million shares at $15.50 in an upsized follow-on underwritten by J.P. Morgan, Goldman Sachs, Cowen, Leerink and BofA Merrill Lynch....
7:25 AM, Feb 23, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

Celularity unveils size of series A

Celularity Inc. (Warren, N.J.) revealed on Feb. 15 that it has raised more than $250 million in series A funding and assets from Celgene Corp. (NASDAQ:CELG), three other biotechs and private investors. The cell therapy,...
7:25 AM, Feb 23, 2018  |  BC Week In Review | Company News  |  Deals

Ipsen seeks to invest in early stage innovation with Arix

Life sciences investment firm Arix Bioscience plc (LSE:ARIX) partnered with Ipsen Group (Euronext:IPN; Pink:IPSEY) to create new companies focused on developing and commercializing "innovative therapies" in undisclosed indications. Arix declined to disclose further details about...
7:25 AM, Feb 23, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Celgene's Otezla meets in Phase III for Behcet's disease

Celgene Corp. (NASDAQ:CELG) reported data from the Phase III RELIEF trial in 207 active Behcet's disease patients with oral ulcers showing that twice-daily oral 30 mg Otezla apremilast (CC-10004) met the primary endpoint of reducing...
7:24 AM, Feb 23, 2018  |  BC Week In Review | Financial News  |  Proposed Offerings

Addex proposes CHF40M private placement

Neurology company Addex Therapeutics Ltd. (SIX:ADXN) proposed on Feb. 15 to raise up to CHF40 million ($42.7 million) through the sale of 12.8 million shares at CHF3.43 in a private placement. The company said CHF30...
7:24 AM, Feb 23, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

Kallyope raises $66M in series B

Kallyope Inc. (New York, N.Y.) raised $66 million on Feb. 22 in a series B round. Existing investors Lux Capital, The Column Group, Polaris Partners, Illumina Ventures and Alexandria Venture Investments participated, as did new...
7:23 AM, Feb 23, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

Oric raises $50M series C

Cancer company Oric Pharmaceuticals Inc. (South San Francisco, Calif.) said on Feb. 21 it raised $50 million in a series C round from new investors Fidelity Management & Research, Trinitas Capital, Taiho Ventures and NS...
7:23 AM, Feb 23, 2018  |  BC Week In Review | Company News  |  Deals

Merck buying oncolytic virus play Viralytics for $398M

Merck & Co. Inc. (NYSE:MRK) will acquire oncolytic immunotherapy company Viralytics Ltd. (ASX:VLA; OTCQX:VRACY) for A$1.75 per share, or A$502 million ($398 million). The price is a 182% premium to Viralytics’ close of A$0.62 on...
7:23 AM, Feb 23, 2018  |  BC Week In Review | Company News  |  Deals

Takeda, Wave in CNS nucleic acid deal

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) and Wave Life Sciences Ltd. (NASDAQ:WVE) partnered to develop and commercialize nucleic acid therapies to treat CNS diseases. Wave will receive an upfront payment of $170 million, including $110 million in...

Pages